Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
Among patients with IgA nephropathy, treatment with iptacopan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).
Authors
- Dana V. Rizk (ORCID: https://orcid.org/0000-0002-6877-2811)
- Naoki Kashihara (ORCID: https://orcid.org/0000-0002-9487-984X)
- Olympia Papachristofi (ORCID: https://orcid.org/0000-0001-9385-6833)
- Nicolas Guérard
- Vlado Perkovic (ORCID: https://orcid.org/0000-0002-4257-7620)
- Thomas Hach (ORCID: https://orcid.org/0000-0002-2229-1545)
- Tobias Merkel
- Brad H. Rovin (ORCID: https://orcid.org/0000-0001-5639-0210)
- Jonathan Barratt (ORCID: https://orcid.org/0000-0002-9063-7229)
- Ronny Renfurm
- Dmitrij Kollins
- Hernán Trimarchi (ORCID: https://orcid.org/0000-0002-6921-4811)
- Bart Maes (ORCID: https://orcid.org/0000-0001-5084-5130)
- Severina Jacinto-Sanders
- Hong Zhang (ORCID: https://orcid.org/0000-0003-4037-7497)
Institutions
- Novartis (Switzerland) (CH)
- Hospital Británico (UY)
- University of Leicester (GB)
- Kawasaki Medical School (JP)
- Peking University (CN)
- The Ohio State University Wexner Medical Center (US)
- UNSW Sydney (AU)
- University of Alabama at Birmingham (US)
- Peking University First Hospital (CN)
- AZ Delta (BE)
- Hospital Británico de Buenos Aires (AR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1056/nejmoa2410316
- Citations
- 129
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 43.75
Funders
- Novartis